For patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with talazoparib (TALA) plus enzalutamide (ENZA) is better than placebo (PBO) plus ENZA, according to a study presented at the American ...
Feb 17, 2023
0
3
Access to therapies approved over the last decade has significantly lengthened median survival times in patients with metastatic hormone-sensitive prostate cancer. That conclusion comes from a large randomized clinical trial ...
May 2, 2022
0
14
Results of a large study led by UCLA Jonsson Comprehensive Cancer Center researchers could help guide treatment planning for patients with high-risk prostate cancer.
Jan 20, 2022
0
16
Prostate cancer (PC) is one of the leading causes of global cancer-related deaths among men. While a standard systemic therapy called "androgen deprivation therapy" (ADT) is widely administered to reduce the level of androgen—the ...
Oct 19, 2021
0
27
Research led by the Centenary Institute has found that a compound extracted from a commonly cultivated orchid could be a potential new treatment option for prostate cancer.
Sep 20, 2021
0
2
New Edith Cowan University (ECU) research has found that exercise not only has physical benefits for men with prostate cancer, it also helps reduce symptoms of depression and anxiety.
Feb 16, 2021
0
6
Researchers from Boston University School of Medicine (BUSM) have discovered that the protein BRD4 could be an important new target to prevent castration-resistant prostate cancer metastases.
Jul 21, 2020
0
163
(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is ...
May 29, 2020
0
5
(HealthDay)—Most functional differences associated with contemporary management of localized prostate cancer attenuate by five years, according to a study published in the Jan. 14 issue of the Journal of the American Medical ...
Feb 19, 2020
0
1
A prescription of short-term exercise for patients with advanced prostate cancer could help to reduce the side-effects of hormone therapy, according to new research from the University of East Anglia.
Dec 9, 2019
0
2
